High-density lipoprotein cholesterol in coronary artery disease patients: Is it as low as expected?

Anadolu Kardiyoloji Dergisi

Volumn 5, Issue 4, 2005, Pages 268-270

  Uzunlulu, Mehmet ^a,c   Oǧuz, Aytekin ^a   Tigen, Kürşat ^b  

^a SSK Goztepe Training and Research Hospital   (Turkey)

^b KOSUYOLU HEART AND RESEARCH HOSPITAL   (Turkey)

^c Merdivenkoy SSK Poliklinikleri Karsisi   (Turkey)

Author keywords

Coronary artery disease; HDL cholesterol

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE;

ADULT; ANGIOGRAPHY; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHOLESTEROL, HDL; CORONARY ARTERIOSCLEROSIS; FEMALE; HUMANS; LIPID METABOLISM; MALE; MIDDLE AGED; RISK FACTORS; TURKEY;

EID: 29544438629     PISSN: 13028723     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996;124 (Suppl): S11-20.
2. Sacks FM. Expert Group on HDL Cholesterol, The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations. Am J Cardiol 2002; 90:139-43.
3. Mahley RW, Palaoglu KE, Atak Z, et al. Turkish Heart Study: lipids, lipoproteins, and apolipoproteins. J Lipid Res 1995; 36: 839-59.
4. Onat A, Yildirim B, Uslu N, et al. Plasma lipoprotein and apolipoproteins in Turkish adults: overall levels, association with risk factors, and HDL as a predictor of coronary risk in women. Arch Turk Soc Cardiol 1999; 27:72-9.
5. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
6. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol 1995; 75: 1196-201.
7. McLaughlin PR, Gladstone P. Diabetes Atherosclerosis Intervention Study (DAIS): quantitative coronary angiographic analysis of coronary artery atherosclerosis. Cathet Cardiovasc Diagn 1998; 44: 249-56.
8. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 34: 410-8.
9. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000; 284: 1263-70.
10. MRC/BHF Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999; 20: 725-41.
11. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
12. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
13. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
14. Steiner G. Treating lipid abnormalities in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88(Suppl): 37N-40N.